Department of Pathology and Laboratory Medicine David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, CHS 13-145, Los Angeles, CA 90095-1732.
Department of Pathology Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115.
Cardiovasc Pathol. 2014 Mar-Apr;23(2):65-70. doi: 10.1016/j.carpath.2013.10.001. Epub 2013 Oct 8.
Calcific aortic valve disease of the elderly is the most prevalent hemodynamically-significant valvular disease, and the most common lesion requiring valve replacement in industrialized countries. Transcatheter aortic valve implantation is a less invasive alternative to classical aortic valve replacement that can provide a therapeutic option for high-risk or inoperable patients with aortic stenosis. These devices must be biocompatible, have excellent hemodynamic performance, be easy to insert, be securely anchored without sutures, and be durable, without increased risk of thrombosis or infection. To date, complications are related to the site of entry for insertion, the site of implantation (aorta, coronary ostia, base of left ventricle), and to the structure and design of the inserted device. However, as with any novel technology unanticipated complications will develop. Goals for future development will be to make the devices more effective, more durable, safer, and easier to implant, so as to further improve outcome for patients with severe aortic stenosis. The pathologist participating in research and development, and examination of excised devices will have a critical role in improving outcome for these patients.
老年钙化性主动脉瓣疾病是最常见的血流动力学显著瓣膜病,也是工业化国家最常见需要瓣膜置换的病变。经导管主动脉瓣植入术是一种较经典主动脉瓣置换术侵袭性更小的替代方法,可为有主动脉瓣狭窄高危或不能手术的患者提供治疗选择。这些设备必须具有生物相容性、出色的血液动力学性能、易于插入、无需缝合即可安全固定、耐用,且不会增加血栓形成或感染的风险。迄今为止,并发症与插入部位、植入部位(主动脉、冠状动脉口、左心室基部)以及插入设备的结构和设计有关。但是,与任何新的技术一样,可能会出现意外的并发症。未来发展的目标将是使设备更有效、更耐用、更安全、更容易植入,从而进一步改善严重主动脉瓣狭窄患者的预后。参与研究和开发以及检查切除设备的病理学家将在改善这些患者的预后方面发挥关键作用。